German pharmaceutical company Riemser Arzneimittel has acquired the dental business of Curasan.
Curasan had been marketing bone regeneration and membrane products in the U.S. since 2004. Its three leading products include Cerasorb, Epi-Guide, and Revois.
"Given the rapid growth in the U.S. of Cerasorb bone regeneration material and Epi-Guide membrane -- which have doubled in users and sales during each of the past two years -- we are eager to bring additional financial resources to the expansion of these and other dental products," Norman Braun, head of Riemser's dental division, stated in a company press release.
